11.09.24 -- Cell & Gene Best Of October

Adeno-associated virus (AAV) is a prominent vector for gene delivery to treat life-threatening genetic diseases. A limitation for product development and treatment availability is the need for high levels of infectious AAV particles. We'll show that feeding cell cultures post-transfection (HEK293 cells) or post-infection (insect cells) can boost AAV titers. Data will be shared on the optimization of using Cellvento® ModiFeed Prime COMP to boost AAV titers. Register.

It’s not just about the science. This article explores some steps that can be taken now to make the next generation of CGTs affordable and accessible not just approvable.

Advanced cell-based therapies are impossible without high-quality leukopaks from high-quality donors.

Cell clumps may be present prior to administration of your final drug product. In the absence of regulatory guidance, we recommend establishing a risk management strategy for control of particulates.

The importance of early collaboration between drug developers, manufacturers, and payers is evident, as it aids in the creation of meaningful endpoints and the formulation of access strategy.

By partnering with industry experts, biotech startups can enhance their IND applications, ensuring a smoother path to FDA approval and increasing their chances of bringing innovative drugs to market.

Dr. Diana Azzam delves into the details of her work in guiding individualized patient treatments, from her functional precision medicine research into the future standard of care for oncology testing.